AC Immune SA — CureCurrent

How to interpret these research links

Connected source records

The exact organization name AC Immune SA appears in 9 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials9

Recruiting shown4

Roles2

SourceClinicalTrials.gov

Clinical trials

9 shown

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk FactorsNCT07463196 · lead sponsor · 2026-01-28

[18F]ACI-15916 PET in α-synucleinopathiesNCT06891703 · lead sponsor · 2025-03-20

[18F]ACI-19626 PET in TDP-43 ProteinopathiesNCT06891716 · lead sponsor · 2025-01-21

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)NCT05462106 · lead sponsor · 2022-06-21

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's DiseaseNCT06015841 · lead sponsor · 2023-07-24

ACTIVE_NOT_RECRUITING

A Study of ACI-24 in Adults With Down SyndromeNCT04373616 · lead sponsor · 2021-10-01

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseNCT04445831 · lead sponsor · 2019-07-31

Optimization of Morphomer-based Alpha-synuclein PET TracersNCT05067192 · collaborator · 2021-07-15

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the BrainNCT06445465 · collaborator · 2020-12-24

Sponsor roles

lead sponsor7

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.